Study · Case report or series · n = 1 · 2007

1 result

Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.

Sheffield CA, Kane MP, Busch RS

Pharmacotherapy1 Oct 2007Cited by 17 (Europe PMC)

PMID17896900DOI10.1592/phco.27.10.1449PepBankPUB-17896900

Publisher page PubMedAsk about this study

Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

01HumanCase report or seriesSafety outcome
An obese man with type 1 diabetes and HIV infection had gastrointestinal intolerance to pramlintide before receiving exenatide.
In plain wordsA man with type 1 diabetes and HIV had digestive intolerance to pramlintide before he received exenatide.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableGastrointestinal intolerance
Study
n = 1
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
We report the successful off-label use of exenatide in an obese, 40-year-old man with type 1 diabetes and human immunodeficiency virus (HIV) infection who had gastrointestinal intolerance to pramlintide.
Report a problemFND-1789690001

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.